The bacterial challenge - time to react

The European Medicines Agency (EMEA)There is a need for more development of antibiotics that are effective against multidrug-resistant bacteria. That is the conclusion of a new report prepared jointly by the European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMEA) with contributions from the international network Action on Antibiotic Resistance (ReAct). The report is being discussed today in Stockholm by experts at a conference on "Innovative Incentives for Effective Antibacterials", as part of the Swedish Presidency of the European Union.

Bo Aronsson MD, responsible for the EMEA part of the study said: "Industry's pipeline contains very few new antibiotics active against multidrug-resistant bacteria. Without stimulating research and development into new antibiotics, an increasing number of infected patients will be without effective treatment."

Dominique Monnet, responsible for the ECDC part of the study said: "A future without effective antibiotics will exacerbate a situation where already at least 25,000 patients in the EU each year die from infections due to multidrug-resistant bacteria. Patients suffering from healthcare-associated infections will be particularly hard hit."

In 2007, the ECDC, the EMEA and the international network Action on Antibiotic Resistance entered into a discussion on the need to produce a report that reviewed and documented the gap between infections caused by multidrug-resistant bacteria in the EU and the development of new antibiotics to treat them. An ECDC-EMEA joint Working Group was established in 2008 to prepare this report called "The bacterial challenge - time to react. A call to narrow the gap between multi-drug resistant bacteria in the EU and development of new antibacterial agents."

The objective of this report is to give an account of facts and figures that would allow reasonable predictions of the gap between bacterial resistance in the EU and the likely availability of new treatments that would be effective against multidrug-resistant bacteria in the near future. As such, this technical report is made available to the European Commission for consideration. The report also serves as a basis for discussions at today's expert conference on "Innovative Incentives for Effective Antibacterials", as part of the Swedish EU Presidency.

Main findings
The general finding of the report is that there is a gap between the burden of infections due to multidrug-resistant bacteria and the development of new antibiotics to tackle the problem. Specifically, the report finds that:

  • Resistance to antibiotics is high among Gram-positive and Gram-negative bacteria that cause serious infections in humans and reaches 25% or more in several EU Member States. Resistance is increasing in the EU among certain Gram-negative bacteria such as recently observed for Escherichia coli.
  • Each year, about 25,000 patients die in the EU from an infection with the selected multidrug-resistant bacteria.
  • Infections due to these selected multidrug-resistant bacteria in the EU result in extra healthcare costs and productivity losses of at least €1.5 billion each year.
  • Fifteen systemically administered antibacterial agents, with a new mechanism of action or directed against a new bacterial target, were identified as being under development with a potential to meet the challenge of multidrug resistance. Most of these were in early phases of development and were primarily developed against bacteria for which treatment options are already available.
  • There is a particular lack of new agents with new targets or mechanisms of action against multidrug-resistant Gram-negative bacteria. Two such agents with new or possibly new targets and documented activity were identified, both in early phases of development.
  • A European and global strategy to address this gap is urgently needed.

For further information, please download:
http://www.emea.europa.eu/pdfs/human/antimicrobial_resistance/EMEA-576176-2009.pdf

About EMEA
The European Medicines Agency is the European Union body responsible for coordinating the existing scientific resources put at its disposal by Member States for the evaluation, supervision and pharmacovigilance of medicinal products.

The Agency provides the Member States and the institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, safety and efficacy of medicinal products for human or veterinary use referred to it in accordance with the provisions of EU legislation relating to medicinal products.

About ECDC
The European Centre for Disease Prevention and Control (ECDC) is an EU agency tasked with identifying assessing and communicating threats to human health posed by infectious diseases. It supports the work of public health authorities in the EU and EEA/EFTA Member States.

Most Popular Now

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Scientists identify common vulnerabilities across …

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...